Related Experiment Video
Updated: May 21, 2026

Experimental Metastasis Assay
Published on: August 24, 2010
MDM2 binding protein, a novel metastasis suppressor
Tomoo Iwakuma1, Neeraj Agarwal
1Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow blvd., Wahl East, Room 2005, Kansas City, KS 66160, USA. tiwakuma@kumc.edu
Abstract:
MDM2 binding protein (MTBP) is a protein that interacts with oncoprotein murine double minute (MDM2), a major inhibitor of the tumor suppressor p53. Overexpression of MTBP leads to p53-independent cell proliferation arrest, which is in turn blocked by simultaneous overexpression of MDM2. Importantly, reduced expression of MTBP in mice increases tumor metastasis and enhances migratory potential of mouse embryonic fibroblasts regardless of the presence of p53. Clinically, loss of MTBP expression in head and neck squamous cell carcinoma is associated with reduced patient survival, and is shown to serve as an independent prognostic factor when p53 is mutated in tumors. These results indicate the involvement of MTBP in suppressing tumor progression. Our recent findings demonstrate that overexpression of MTBP in human osteosarcoma cells lacking wild-type p53 inhibits metastasis, but not primary tumor growth, when cells are transplanted in femurs of immunocompromised mice. These data indicate that MTBP functions as a metastasis suppressor independent of p53 status. Furthermore, overexpression of MTBP suppresses cell migration and filopodia formation, in part, by inhibiting function of an actin crosslinking protein α-actinin-4. Thus, increasing evidence indicates the significance of MTBP in tumor progression. We summarize published results related to MTBP function and discuss caveats and future directions in this review article.
Insights
MDM2 binding protein (MTBP) suppresses tumor metastasis independently of p53. Reduced MTBP expression correlates with poorer survival in head and neck cancers, highlighting its role in cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- MDM2 binding protein (MTBP) interacts with MDM2, a key inhibitor of tumor suppressor p53.
- MTBP influences cell proliferation and migration, with implications for tumor progression.
- Loss of MTBP expression is linked to reduced survival in head and neck squamous cell carcinoma.
Purpose of the Study:
- To review and summarize the known functions of MTBP in tumor progression.
- To highlight MTBP's role as a potential metastasis suppressor.
- To discuss future research directions for MTBP in cancer therapy.
Main Methods:
- Review of published literature on MTBP function.
- Analysis of clinical data linking MTBP expression to patient survival.
- Experimental data on MTBP's effect on cell metastasis and migration in osteosarcoma models.
Main Results:
- MTBP overexpression inhibits metastasis and cell migration, independent of p53 status.
- Reduced MTBP expression enhances tumor metastasis and cell migratory potential in mice.
- MTBP acts as a metastasis suppressor by inhibiting α-actinin-4 function.
Conclusions:
- MTBP is a significant factor in suppressing tumor metastasis.
- MTBP's role in cancer progression is independent of the p53 pathway.
- Further research into MTBP's mechanisms and therapeutic potential is warranted.
Related Concept Videos
Abnormal Proliferation
Master Transcription Regulators
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
MicroRNAs
MicroRNAs
Mitogens and the Cell Cycle
